Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity (NCT05132231)
CARE: A CAnadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity
🩺 Plain-English Summary (8th-Grade Level)
This is a phase IV, 12-month observational, prospective, open-label, multi-center study that will be conducted across approximately 50 sites in Canada for an estimated study duration of 32 months. All eligible adult participants who are enrolling into the SILIQ Patient Support Program (PSP) and initiating brodalumab as per routine care may be offered participation in the study. If the participant agrees, their verbal consent and details will be entered into the study platform by the enrolling physician so that the participant can access the electronic informed consent form. Participants who meet the eligibility criteria and provide electronic informed consent will be enrolled in the study. The study observation period will be 12 months (±15 days). Data will be collected on approximately 500 participants across academic and community centers.
Who can join: Review the eligibility criteria below.
Location: CARE Site 42 — Calgary, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (42 Sites)
Showing the first 25 of 42 sites.
- CARE Site 42 — Calgary, Alberta
- CARE Site 26 — Calgary, Alberta
- CARE Site 15 — Calgary, Alberta
- CARE Site 18 — Edmonton, Alberta
- CARE Site 41 — Edmonton, Alberta
- CARE Site 21 — Edmonton, Alberta
- CARE Site 37 — Edmonton, Alberta
- CARE Site 28 — Sherwood Park, Alberta
- CARE Site 31 — Vancouver, British Columbia
- CARE Site 36 — Winnipeg, Manitoba
- CARE Site 12 — Winnipeg, Manitoba
- CARE Site 35 — Saint Johns, Newfoundland and Labrador
- CARE Site 11 — Ajax, Ontario
- CARE Site 05 — Barrie, Ontario
- CARE Site 06 — Greater Sudbury, Ontario
- CARE Site 20 — Guelph, Ontario
- CARE Site 14 — Hamilton, Ontario
- CARE Site 24 — Hamilton, Ontario
- CARE Site 23 — London, Ontario
- CARE Site 22 — London, Ontario
- CARE Site 09 — London, Ontario
- CARE Site 33 — Markham, Ontario
- CARE Site 44 — Mississauga, Ontario
- CARE Site 51 — Niagara Falls, Ontario
- CARE Site 48 — North York, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriasis
- Deucravacitinib Adherence Study — Winston-Salem, North Carolina
- An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects — San Diego, California
- Psoriasis Longitudinal Assessment and Registry — Birmingham, Alabama
- Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 — Birmingham, Alabama
- Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Birmingham, Alabama
- Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis — Scottsdale, Arizona
Explore by condition: All Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.